Aclaris Therapeutics (ACRS) Tops Q4 EPS by 17c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Aclaris Therapeutis (ACRS): Eskata and Pipeline Should Drive Shares Higher - Cantor Fitzgerald
March 12, 2018 11:19 AM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $50 price target on Aclaris Therapeutis (NASDAQ: ACRS), saying Eskata and the pipeline should drive share higher.
Chen commented, "Post a solid quarter of execution, and ahead of important catalysts for the company, we... More
Aclaris Therapeutics (ACRS) Announces U.S. Patent for JAK Inhibitor to Treat Hair Loss
March 9, 2018 8:02 AM ESTAclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,895,301, which is directed to methods related to the use and administration of a certain janus kinase (JAK) inhibitor for treating hair loss disorders.
U.S. Patent No. 9,895,301 covers the use of tofacitinib for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia (AGA), otherwise known as male/female pattern hair loss. Additional issued claims pertain to methods of... More
